0001104659-21-131684.txt : 20211202 0001104659-21-131684.hdr.sgml : 20211202 20211029140513 ACCESSION NUMBER: 0001104659-21-131684 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20211029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synthetic Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970730 CORRESP 1 filename1.htm

A picture containing text, clipart

Description automatically generated

October 29, 2021

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance

100 F Street, N.E.
Washington, D.C. 20549

Re:

Synthetic Biologics, Inc.

Registration Statement on Form S-3

File No: 333-260449

Request For Acceleration

Ladies and Gentlemen:

Synthetic Biologics, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-260449), to become effective on Tuesday, November 2, 2021, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. or Patrick J. Egan, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 or Mr. Egan at (914) 557-5574 or (212) 907-6457 with any questions you may have concerning this request, and please notify her or him when this request for acceleration has been granted.

	Very truly yours,

	Synthetic Biologics, Inc.

	By:	/s/ Steven A. Shallcross
		Name: Steven A. Shallcross
		Title: Chief Executive Officer and Chief Financial Officer

cc:	Leslie Marlow, Esq., Gracin & Marlow, LLP Patrick J. Egan, Esq., Gracin & Marlow, LLP

GRAPHIC 2 tm2131387d1_correspimg001.jpg GRAPHIC begin 644 tm2131387d1_correspimg001.jpg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end